Lunesta Schedule IV Placement Effective Immediately, DEA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Drug Enforcement Administration's final rule designates Lunesta (eszoplicone) as a Schedule IV controlled substance. Sepracor planned to launch the insomnia agent on the day of the ruling.